BOULDER - Medical-device maker Covidien Plc said Thursday that it will start selling a new patient monitoring system following approvals from the U.S. Food and Drug Administration and a European regulatory agency.

Covidien's (NYSE: COV) new Nellcor Bedside Respiratory Patient Monitoring System will be marketed and sold by the company's respiratory and monitoring solutions business unit in Gunbarrel. The new machine is not available for sale, yet, but it will be in the next few months, said Caitlin Mayer, a company spokeswoman. Mayer declined to discuss the sales price of the machine.

The machine monitors blood oxygenation, pulse rate and other data to help clinicians respond to patient respiratory events quickly, according to a press release. It features a color touch-screen monitor and uses the same base OxiMax technology as the company's Nellcor Bedside Sp02 Patient Monitoring System approved by the FDA in July, Mayer said.

The Covidien respiratory and monitoring unit has about 400 employees. Covidien has 1,400 employees working at a local surgical-device unit. The company opened an $18 million, 63,000-square-foot research and development center in Gunbarrel in March. Worldwide, Covidien posted $11.6 billion in revenue in 2011.